logo
Quest Diagnostics Introduces Testing for Oropouche Virus

Quest Diagnostics Introduces Testing for Oropouche Virus

Diagnostic testing for emerging infectious disease associated with severe neurological affects
SECAUCUS, N.J., July 15, 2025 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging disease that is increasingly found in South and Central America and the Caribbean.
'As one of the leading providers of laboratory testing, Quest plays an essential role in ensuring the U.S. is prepared to respond to potentially dangerous emerging diseases, such as Oropouche virus,' said Yuri Fesko, MD, Senior Vice President and Chief Medical Officer at Quest Diagnostics. 'By developing this test, we are prepared to act quickly to offer scalable testing to complement public health labs should this virus become a public health threat.'
Oropouche virus is an emerging virus in the Americas that is spread to people by infected biting midges and some mosquito species. While the current threat to the public in North America remains low, Oropouche virus has been reported in parts of South America, Central America and the Caribbean, with the majority of infected individuals becoming symptomatic. Cases reported in the United States have been limited to travelers returning from countries with local transmission. Oropouche viral disease presents clinically with symptoms that overlap with those of other arboviral diseases such as Dengue, Zika and chikungunya. While most people recover on their own, Oropouche virus can also cause more severe neuroinvasive disease like meningitis and encephalitis.
The test will be available with a prescription from a provider for clinical purposes at the end of the month. Quest's advanced laboratory in San Juan Capistrano, California, developed and will perform the test using polymerase chain reaction (PCR) technology, with serology testing to follow later this quarter. Reverse transcription PCR testing can identify the RNA of the virus during the early stages of infection to aid diagnosis. Serology testing, which identifies antibodies produced by the immune system in response to the virus, can help diagnose the virus in later stages of infection.
In September 2024, Quest Diagnostics was awarded several contracts by the U.S. Centers for Disease Control and Prevention (CDC) to support testing and sustained laboratory readiness for emerging infectious diseases, including the development of diagnostics to aid the detection of Oropouche virus. The company also launched the first commercially available diagnostic test for Avian Influenza A H5 based on the funding. The contracts provide funding to enable the company to maintain testing readiness, such as for adequate supplies of certain equipment and chemical reagents used to perform the tests, on a sustained basis, should the U.S. need to quickly mobilize response to safeguard public health.
About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New ASTHO Legal Map Illuminates State and Territorial Suicide Prevention Infrastructure
New ASTHO Legal Map Illuminates State and Territorial Suicide Prevention Infrastructure

Malaysian Reserve

time4 hours ago

  • Malaysian Reserve

New ASTHO Legal Map Illuminates State and Territorial Suicide Prevention Infrastructure

ARLINGTON, Va., July 24, 2025 /PRNewswire/ — The Association of State and Territorial Health Officials (ASTHO), in partnership with Temple University and with support from the Centers for Disease Control and Prevention (CDC), today announced the release of a new interactive resource, Legal Mapping of State and Territorial Infrastructure to Prevent Suicides. The tool visualizes state and territorial laws, as of January 1, 2025, related to suicide prevention commissions, offices, and fatality review processes, providing invaluable insights for strengthening prevention efforts nationwide. Suicide remains a significant public health crisis, ranking as the second-leading cause of death for individuals ages 10-34 in 2023, with over 49,000 suicides occurring across all age groups that year. Certain populations experience disproportionately higher rates of suicide, including those in rural areas, older adults, American Indian or Alaska Native individuals, people with disabilities, and veterans. 'Understanding the variability of legal frameworks for suicide prevention infrastructure across jurisdictions can help leaders identify ways they might strengthen their own work,' says Joseph Kanter, MD, MPH, ASTHO CEO. 'These new legal maps help jurisdictions examine the national landscape of policies, enable health agencies to pinpoint gaps, replicate best practices, and strategically implement evidence-based interventions tailored to their communities' unique needs. Strong, legally supported infrastructure is paramount to sustaining prevention efforts, especially amid evolving funding landscapes.' The interactive resource allows users to explore various aspects of state and territorial suicide prevention infrastructure, including: The establishment of suicide prevention offices or coordinators The existence of population-focused suicide prevention groups or taskforces The establishment and scope of committees or bodies that review suicide fatalities, including data collection on suicide attempts and information sharing requirements Key findings regarding the legal landscape of state-level infrastructure as of January 1, 2025: Twelve jurisdictions had laws establishing a suicide prevention office or coordinator, with eight of these offices located within health departments Twelve jurisdictions have laws establishing suicide prevention task forces, commissions, or other advisory bodies Thirty jurisdictions had a law establishing a committee, body, or other review process for some portion of suicide fatalities On July 30, ASTHO is hosting a webinar focused on the new resource. Register here: State and Territorial Infrastructure for Suicide Prevention: Exploring New Legal Maps. ASTHO is the national nonprofit organization representing the public health agencies of the United States, the U.S. territories and freely associated states, and Washington, D.C., as well as the more than 100,000 public health professionals these agencies employ. ASTHO members, the chief health officials of these jurisdictions, are dedicated to formulating and influencing sound public health policy and to ensuring excellence in public health practice.

Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025
Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

Malaysian Reserve

time10 hours ago

  • Malaysian Reserve

Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts in Chicago, July 28–31 Unifying global diagnostic data – STAgora™, the big data platform set to transform the future of diagnostics Offering early access to the new diagnostic paradigm, pilot partnerships with selected institutions engaged by year-end SEOUL, South Korea , July 24, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world's largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm. Automating every step of PCR Testing for enhanced efficiency and accuracy CURECA™ is the world's first system to fully automate the entire PCR testing process – from sample storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results. A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in laboratory workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their high viscosity and particulates, requiring heavy manual handling. The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major sample types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high volume, 24/7 continuous testing environments to provide sustainable high quality testing results. In addition, the prep module of CURECA™ system is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory. STAgora™ – Real-Time Global Data Integration & Analysis Empowering Personalized Care Also unveiled at ADLM 2025, STAgora™ is Seegene's statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support. With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making. Expanding Global Collaboration via Technology Sharing and Strategic Partnerships Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships. Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe's leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA. 'CURECA™ and STAgora™ are more than just diagnostics instrument or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we've built over the years and based on this, we are committed to driving fundamental innovation across the global diagnostics ecosystem.' Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene. Disclaimer The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. Visit: and follow

Kings View and "Empowered with Meg Ryan" Join Forces to Navigate Life's Mental Health Journey
Kings View and "Empowered with Meg Ryan" Join Forces to Navigate Life's Mental Health Journey

Malaysian Reserve

time12 hours ago

  • Malaysian Reserve

Kings View and "Empowered with Meg Ryan" Join Forces to Navigate Life's Mental Health Journey

LOS ANGELES, July 24, 2025 /PRNewswire/ — Public Television viewers are invited to explore a vital conversation on well-being as 'Empowered with Meg Ryan' partners with Kings View for an upcoming segment. This collaboration aims to provide a fresh perspective on a universal experience: navigating the complexities of mental health and finding support. This insightful segment of 'Empowered with Meg Ryan', set to film later this year in Fresno, California, will gently guide Public Television audiences through the often-unseen landscape of behavioral health. It will unpack why many find it challenging to seek help, revealing that, on average, individuals may endure mental health or substance use issues for over nine years before reaching out. The program will highlight King's View's comprehensive approach, from their Mental Health Minute vignettes – short, impactful messages addressing topics such as grief and suicide – to their innovative wellness centers, partnerships with law enforcement, outpatient treatment, walk-in therapy clinic, telepsychiatry options, crisis debriefing, medically assisted SUD support, homeless outreach, and crucial warm line and hotline services. This segment will highlight how these diverse avenues offer access to thousands who might otherwise suffer in silence, fostering a community where seeking help is normalized and accessible to all ages and demographics. 'Mental health is not a guarantee—it's a daily investment. Wellness doesn't just happen; it's something we all have to nurture, protect, and prioritize.' — Amanda Nugent Divine, CEO The segment will offer a compelling look at how Kings View is working to reduce the stigma surrounding behavioral health across various communities and socio-economic levels. It will underscore the powerful message that just as we readily address physical ailments, mental health challenges deserve the same immediate attention and compassionate care. Viewers will discover that help is readily available, and early intervention can often prevent prolonged struggles, even potentially preventing a lifetime of suffering or worse. The program will also explore the broad spectrum of approaches to well-being, from mindfulness practices and meditation to effective medications that work effectively. It will emphasize that there is no shame in seeking support, whether for common issues like depression or anxiety, or more profound challenges. This captivating exploration is designed to inspire individuals to acknowledge their needs and embrace the path to healing, fostering a more open and understanding dialogue around mental well-being for everyone. The segment hopes to educate hundreds of thousands of people, broadcasting a message that resonates with millions and streams globally online. About 'Empowered with Meg Ryan': 'Empowered with Meg Ryan' is a Public Television program that offers viewers valuable insights and educational content, inspiring them to take informed action in their lives and communities. The program highlights organizations that are making a positive impact and providing pathways to greater well-being. Learn more at: About Kings View: Kings View has remained committed to providing timely, accessible, person-centered behavioral healthcare services throughout California and has been doing so for 75 years. Today, their network of programs continues to offer a comprehensive range of mental health, substance use disorder, and other supportive services, dedicated to fostering wellness and reducing the stigma associated with behavioral health challenges. Learn more at:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store